Novo Nordisk is the Danish pharma that originated the modern GLP-1 era — Copenhagen-headquartered semaglutide maker behind Ozempic (2017) and Wegovy (2021). Briefly Europe's most valuable public company September 2023.
Ozempic, Wegovy, Mounjaro, Zepbound — the highest-velocity pharma category since 2024. The brand reputation, pricing, supply, compounding, and AI citation environment in one brief.
Novo Nordisk owns the diabetes GLP-1 answer. Eli Lilly owns the weight-loss answer. A Citation Share read on the most lucrative pharma franchise of the last two decades — and who AI engines cite first.
The wellness industry outgrew the media infrastructure that once covered it. AI engines now fill the trust vacuum. Everything-PR's complete cluster on wellness communications and AI visibility in a $1.8 trillion category.
Novo Nordisk's Ozempic threatened $1.8T wellness. GLP-1s reset the consumer contract. Levels and Function survived. Weight-loss supplement SKUs got pulled.